<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984863</url>
  </required_header>
  <id_info>
    <org_study_id>RuijinH20190228</org_study_id>
    <nct_id>NCT04984863</nct_id>
  </id_info>
  <brief_title>MCCE in Assessing Efficacy of Gastro-oesophageal Varices</brief_title>
  <official_title>Clinical Usefulness of Magnetically Controlled Capsule Endoscopy in Assessing Efficacy of Gastro-oesophageal Varices in Patients With Liver Cirrhosis Treated Under Gastroscopy: a Prospective, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposed for the first time the use of MCE to evaluate the efficacy of the&#xD;
      treatment of gastroesophageal varices, and compared the examination results with the gold&#xD;
      standard to explore whether MCE could replace the electronic gastroscopy as the preferred&#xD;
      non-invasive evaluation method for the treatment of gastroesophageal varices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastro-esophageal varices is one of the complications of portal hypertension in cirrhosis.&#xD;
      For patients with moderate to severe varicose veins, international guidelines recommend&#xD;
      active treatment, including endoscopic therapy such as endoscopic band ligation (EBL) and&#xD;
      interventional radiotherapy such as balloon-occluded retrograde transvenous obliteration&#xD;
      (B-RTO)Electronic gastroscopy is the gold standard for the diagnosis of varicose veins at&#xD;
      higher blood risk (varicose veins requiring retreatment). However, it is relatively invasive&#xD;
      and uncomfortable in the examination process, so that patients with gain-and-compensation&#xD;
      cirrhosis are often unwilling to accept it, which is not conducive to the standardized&#xD;
      follow-up after the treatment of gastro-esophageal varices.Magnetically controlled capsule&#xD;
      endoscopy (MCE) is a non-invasive detection method independently developed in China that&#xD;
      covers the whole digestive tract (except colon) mucosa. Patients only need to swallow a&#xD;
      capsule endoscope to make repeated observation for many times, and the examination process is&#xD;
      painless. It is an ideal method for diagnosing varicose veins with high blood risk (varicose&#xD;
      veins that need treatment). Therefore, this study proposed for the first time the use of MCE&#xD;
      to evaluate the efficacy of the treatment of gastroesophageal varices, and compared the&#xD;
      examination results with the gold standard to explore whether MCE could replace the&#xD;
      electronic gastroscopy as the preferred non-invasive evaluation method for the treatment of&#xD;
      gastroesophageal varices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the clinical usefulness of MCE in assessing the efficacy of gastro-oesophageal varices treated under gastroscopy.</measure>
    <time_frame>15-30 minutes</time_frame>
    <description>Comparing the value of MCE and gastroscopy in the grading of esophagogastric varices</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Gastroesophageal Varices</condition>
  <arm_group>
    <arm_group_label>magnetically controlled capsule endoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetically controlled capsule endoscopy</intervention_name>
    <description>Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.</description>
    <arm_group_label>magnetically controlled capsule endoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years old&#xD;
&#xD;
          -  Confirmed cirrhosis by clinical or pathological biopsy&#xD;
&#xD;
          -  Previous endoscopic treatment of esophageal and gastric varices, including but not&#xD;
             limited to sclerotherapy, injection of tissue adhesives, skin entrapment, etc&#xD;
&#xD;
          -  Electronic gastroscopy is to be performed&#xD;
&#xD;
          -  Voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Absolute contraindications:&#xD;
&#xD;
          -  Patients without surgical conditions or refusing any abdominal surgery (once the&#xD;
             capsule is stranded, it cannot be removed by surgery)&#xD;
&#xD;
          -  There is a pacemaker in the body, except that the pacemaker is a new MRI compatible&#xD;
             product&#xD;
&#xD;
          -  Electronic devices such as cochlear implants, magnetic metal drug infusion pumps,&#xD;
             nerve stimulators and magnetic metal foreign bodies are implanted in the body;&#xD;
&#xD;
          -  .Women during pregnancy&#xD;
&#xD;
        Relative contraindication:&#xD;
&#xD;
          -  Gastrointestinal obstruction, stenosis, and fistula are known or suspected&#xD;
&#xD;
          -  Dysphagia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duowu Zou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duowu Zou, M.D.</last_name>
    <phone>+86-13901617608</phone>
    <email>zdw12125@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Zhang, M.D.</last_name>
      <phone>+86-18019076695</phone>
      <email>zyrjxh97@sjtu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Duowu Zou, M.D.</last_name>
      <phone>+86-13901617608</phone>
      <email>zdw12125@rjh.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10. Erratum in: J Hepatol. 2018 Nov;69(5):1207.</citation>
    <PMID>29653741</PMID>
  </results_reference>
  <results_reference>
    <citation>Cremers I, Ribeiro S. Management of variceal and nonvariceal upper gastrointestinal bleeding in patients with cirrhosis. Therap Adv Gastroenterol. 2014 Sep;7(5):206-16. doi: 10.1177/1756283X14538688. Review.</citation>
    <PMID>25177367</PMID>
  </results_reference>
  <results_reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.</citation>
    <PMID>27786365</PMID>
  </results_reference>
  <results_reference>
    <citation>Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005 Nov 24;353(21):2254-61.</citation>
    <PMID>16306522</PMID>
  </results_reference>
  <results_reference>
    <citation>Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, Attili AF, Riggio O. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003 Mar;38(3):266-72.</citation>
    <PMID>12586291</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

